METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

Post-LOE

metoprolol tartrate and hydrochlorothiazide

PharmaIN

ANDAORALTABLET

Approved

Nov 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE (metoprolol tartrate and hydrochlorothiazide) by PharmaIN is clinical pharmacology metoprolol metoprolol is a beta-adrenergic receptor blocking agent. Approved for hypertension this fixed-combination drug is not indicated for initial therapy of hypertension, hypertension. First approved in 2013.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Metoprolol Metoprolol is a beta-adrenergic receptor blocking agent. In vitro and in vivo animal studies have shown that it has a preferential effect on beta 1 adrenoreceptors, chiefly located in cardiac muscle. This preferential effect is not absolute, however, and at higher…

Worked on METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

Mechanism of Action

Indications (2)